EMILY HAAS: Open Payments
NPI 1437571791 · SUNBURY, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,717 in 95 payments from 17 companies in 2025. Trend: 2023 $1,744 · 2024 $2,164 · 2025 $1,717
Food & beverage: $1,717
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $354 |
| Novo Nordisk Inc | 18 | $334 |
| PFIZER INC. | 12 | $190 |
| Lilly USA, LLC | 8 | $157 |
| AstraZeneca Pharmaceuticals LP | 8 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $102 |
| Amgen Inc. | 5 | $80 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Dexcom, Inc. | 3 | $67 |
| Exact Sciences Corporation | 3 | $59 |
Products named: VRAYLAR, Ozempic, ELIQUIS, JARDIANCE, CAPLYTA, QULIPTA, Wegovy, MOUNJARO.
Industry payments across PA — which companies pay providers there.
